The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients
NCT00002363
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Peptide Construction 3, Synthetic
Sponsor
Columbia Research Laboratories